Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Clinical genetics

Building Your Care Team and Treatment Strategy

At a Glance

For ZTTK, RAUST, and MTSS2-related IDDOF, there is no single treatment plan. Care is tailored to the person's gene and symptoms, combining developmental therapies with specialist monitoring for seizures, spine and bone health, growth, feeding, and daily function.

Managing a syndrome like ZTTK, RAUST, or MTSS2-related IDDOF is not about finding a single cure, but about building a supportive framework that grows with the individual. Because these conditions are ultra-rare, care will likely be phenotype-directed—meaning treatment is tailored to the specific symptoms and the exact gene involved, rather than a “one-size-fits-all” protocol [1][2].

Assembling Your Multidisciplinary Team

A “multidisciplinary” team is a group of specialists who work together to address every aspect of health. While it can feel like a lot of appointments, having experts in each area ensures no part of development is overlooked [3][4].

  • The Core Coordinator: This is usually a Clinical Geneticist, Developmental Pediatrician, or a dedicated complex-care physician. They serve as the “hub” for care [5][6].
  • Neurology: Focuses on managing hypotonia (low muscle tone), monitoring for seizures, and tracking developmental progress [1][7].
  • Orthopedics: Specialized in monitoring bone growth and spinal alignment. They watch for signs of scoliosis (side-to-side curve) or kyphosis (forward hunch) [8][9].
  • Rehabilitation (Physiatry): Focuses on physical function, mobility, and the equipment (like braces or walkers) that may help [10][11].

The “Standard of Care”: Individualized Intervention

For the neurodevelopmental parts of the diagnosis, the most effective support is individualized intervention. Research shows that therapies can lead to important improvements in motor skills, language, and social interaction at any age, and should be started as soon as a need is identified [12][13].

  • Physical Therapy (PT): Works on “gross motor” skills like sitting, crawling, and walking. It also helps prevent joint stiffness (contractures) [14][15].
  • Occupational Therapy (OT): Focuses on “fine motor” skills (using hands) and adaptive behaviors (everyday tasks like feeding or dressing) [16][17].
  • Speech-Language Pathology (SLP): Helps with communication—whether through spoken words, signs, or “talker” devices—and addresses feeding or chewing difficulties [18][19].

Managing Skeletal and Neurological Health

Treatment strategies for rare syndromes focus on preventing complications and improving comfort, guided by the specific gene:

  • Skeletal Monitoring: Because many of these syndromes involve delayed bone age or spinal differences, physical exams are standard [20][9]. Imaging like X-rays are typically ordered based on the exact gene and specific clinical findings, rather than on a blanket schedule, to avoid unnecessary radiation. If scoliosis becomes severe, options include specialized bracing or, in some cases, surgical correction [8].
  • Seizure Management: If epilepsy develops, antiseizure medications are selected individually by a neurologist based on seizure type, EEG findings, and potential side effects [21][22]. There is no single preferred drug for these syndromes.
  • Growth Support: If an individual has severe growth restriction, endocrinology evaluation is needed. Treatments like growth hormone therapy require a confirmed deficiency by a pediatric endocrinologist and a careful risk-benefit review, as it is not appropriate for all genetic conditions [23][24].

Coordinating Care Locally

You do not need to live near a major research hospital to get great care. Many families use a “hybrid” model: visiting an Expert Center (like a university genetics clinic) for a “master plan” and then having that plan carried out by local doctors and therapists closer to home [4][25].

When vetting local specialists, look for those who are “learners.” An ultra-rare diagnosis means the doctor may need to read the latest research or consult with the geneticist. A provider who is willing to learn is often the best advocate [26][27].

Common questions in this guide

Who can coordinate medical care for ZTTK, RAUST, or MTSS2-related IDDOF?
A clinical geneticist, developmental pediatrician, or complex-care physician can act as the main coordinator. This person helps neurology, orthopedics, rehabilitation, therapists, and other clinicians share information and follow one care plan.
What therapies are commonly used for developmental delays in these syndromes?
Physical therapy supports movement and helps prevent stiff joints, occupational therapy supports hand skills and everyday activities, and speech-language therapy supports communication, feeding, and chewing. Goals should be tailored to the person's abilities and needs, and therapy can help at any age.
How are scoliosis and kyphosis monitored?
Clinicians use physical examinations to monitor spinal alignment, and X-rays are ordered when the person's gene or clinical findings make imaging appropriate. If scoliosis becomes severe, treatment may include specialized bracing or, in some cases, surgery.
How is epilepsy treated in these rare genetic syndromes?
If seizures develop, a neurologist chooses an antiseizure medicine based on the seizure type, EEG results, and possible side effects. There is no single medication that is best for everyone with these syndromes.
When might growth hormone be considered?
Growth hormone is not appropriate for every genetic syndrome. It may be considered only when severe growth restriction is present and a pediatric endocrinologist confirms a true growth hormone deficiency after reviewing potential benefits and risks.
Can care be managed locally if we live far from a rare-disease center?
Yes. Many families visit a university genetics clinic or other expert center for an overall plan and then work with local doctors and therapists to carry it out. A local clinician who is willing to review research and consult the geneticist can be an important partner.
What should families do about feeding or swallowing difficulties?
A speech-language pathologist can assess communication, chewing, and feeding needs and recommend safer ways to eat or communicate. Ask the care team about swallowing precautions if feeding safety or possible aspiration is a concern.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Neurodevelopmental delay-intellectual disability-skeletal defects syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Who will serve as the 'lead' coordinator to ensure all our different specialists (genetics, neurology, orthopedics) are communicating?
  2. 2.Based on current muscle tone and movement, what specific goals should we set for physical and occupational therapy this year?
  3. 3.Is the current spinal alignment healthy, and how often should we screen for scoliosis or kyphosis based on the specific gene?
  4. 4.What is our 'seizure action plan' if we notice new staring spells or convulsions, and who do we call first?
  5. 5.Are there any specific feeding or swallowing safety precautions we should take, given the risk of aspiration or chewing difficulties?

References

References (27)
  1. 1

    Establishing the phenotypic spectrum of ZTTK syndrome by analysis of 52 individuals with variants in SON.

    Dingemans AJM, Truijen KMG, Kim JH, et al.

    European journal of human genetics : EJHG 2022; (30(3)):271-281 doi:10.1038/s41431-021-00960-4.

    PMID: 34521999
  2. 2

    Identification and Functional Analysis of a Novel NSD2 Missense Variant in a Patient With Rauch-Steindl Syndrome.

    Xu S, Li G, He Y, et al.

    Molecular genetics & genomic medicine 2026; (14(6)):e70238 doi:10.1002/mgg3.70238.

    PMID: 42216445
  3. 3

    Consensus recommendations on organization of care for individuals with Phelan-McDermid syndrome.

    van Eeghen AM, Stemkens D, Fernández-Fructuoso JR, et al.

    European journal of medical genetics 2023; (66(7)):104747 doi:10.1016/j.ejmg.2023.104747.

    PMID: 37003574
  4. 4

    Development of models of care coordination for rare conditions: a qualitative study.

    Walton H, Simpson A, Ramsay AIG, et al.

    Orphanet journal of rare diseases 2022; (17(1)):49 doi:10.1186/s13023-022-02190-3.

    PMID: 35164822
  5. 5

    Multidisciplinary Care of Patients with Inherited Metabolic Diseases and Epilepsy: Current Perspectives.

    Tumienė B, Del Toro Riera M, Grikiniene J, et al.

    Journal of multidisciplinary healthcare 2022; (15()):553-566 doi:10.2147/JMDH.S251863.

    PMID: 35387391
  6. 6

    Parents' expectations regarding case management for rare diseases in Switzerland: mixed-method findings from an online survey.

    Von Mengershausen U, Streuli JC

    Swiss medical weekly 2024; (154()):3401 doi:10.57187/s.3401.

    PMID: 38875522
  7. 7

    A tiered decisional framework for genetic epileptic syndromes with or without encephalopathies: from standard care to investigational strategies.

    Perilli L, Ferretti A, Riva A, et al.

    Expert review of clinical pharmacology 2026; (19(4)):383-401 doi:10.1080/17512433.2026.2652967.

    PMID: 41914479
  8. 8

    Anesthesia of the Patient with Zhu-Tokita-Takenouchi-Kim (ZTTK) Syndrome: A Case Report.

    Hudec J, Kosinova M

    Children (Basel, Switzerland) 2022; (9(6)) doi:10.3390/children9060869.

    PMID: 35740806
  9. 9

    MTSS2-related neurodevelopmental disorder: Further delineation of the phenotype.

    Corona-Rivera JR, Zenteno JC, Ordoñez-Labastida V, et al.

    European journal of medical genetics 2023; (66(10)):104826 doi:10.1016/j.ejmg.2023.104826.

    PMID: 37657631
  10. 10

    Neurological phenotype of Potocki-Lupski syndrome.

    Ciaccio C, Pantaleoni C, Milani D, et al.

    American journal of medical genetics. Part A 2020; (182(10)):2317-2324 doi:10.1002/ajmg.a.61789.

    PMID: 33043631
  11. 11

    Assessment of Balance Parameters in Children with Weakened Axial Muscle Tone Undergoing Sensory Integration Therapy.

    Jacewicz J, Dziuba-Słonina A, Chwałczyńska A

    Children (Basel, Switzerland) 2023; (10(5)) doi:10.3390/children10050845.

    PMID: 37238393
  12. 12

    Effectiveness of Early Intervention Programs for Young Children with Global Developmental Delay: A Systematic Review :.

    Almuhanna SM, Alshehri OA, B Alsaadoon BM, et al.

    Galen medical journal 2025; (14()):e3906 doi:10.31661/gmj.vi.3906.

    PMID: 42038902
  13. 13

    A multicenter clinical study on parent-implemented early intervention for children with global developmental delay.

    Dong P, Xu Q, Zhang Y, et al.

    Frontiers in pediatrics 2023; (11()):1052665 doi:10.3389/fped.2023.1052665.

    PMID: 36873631
  14. 14

    A novel frame shift mutation in STIM1 gene causing primary immunodeficiency.

    Derakhshan D, Taherifard E, Taherifard E, et al.

    Intractable & rare diseases research 2020; (9(2)):109-112 doi:10.5582/irdr.2020.01020.

    PMID: 32494559
  15. 15

    Designing rare disease care pathways in the Republic of Ireland: a co-operative model.

    Ward AJ, Murphy D, Marron R, et al.

    Orphanet journal of rare diseases 2022; (17(1)):162 doi:10.1186/s13023-022-02309-6.

    PMID: 35410222
  16. 16

    Bridging medicine and education for global developmental delay: a cluster sampling study on screening, diagnosis, and intervention in preschool children.

    Zhang Y, Zhang L

    Frontiers in public health 2026; (14()):1860897 doi:10.3389/fpubh.2026.1860897.

    PMID: 42656501
  17. 17

    Efficacy of early clinical interventions for children with global developmental delay.

    Li F, Tian J, Yuan F, et al.

    The International journal of neuroscience 2025; (135(3)):280-286 doi:10.1080/00207454.2023.2298715.

    PMID: 38284177
  18. 18

    MTSS2 -Related Disorder: Refining the Phenotype in Four New Cases and Literature Review.

    Dominicis A, Sparascio FP, Stregapede F, et al.

    American journal of medical genetics. Part A 2025; (197(6)):e64010 doi:10.1002/ajmg.a.64010.

    PMID: 39890443
  19. 19

    [Zhu-Tokita-Takenouchi-Kim syndrome in a neonate].

    Liu WN, Pi YL, Bai XY, Chen HF

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(3)):373-376 doi:10.7499/j.issn.1008-8830.2409076.

    PMID: 40105086
  20. 20

    Clinical details of individuals with Rauch-Steindl syndrome due to NSD2 truncating variants.

    Nishi E, Yanagi K, Kaname T, Okamoto N

    Molecular genetics & genomic medicine 2024; (12(2)):e2396 doi:10.1002/mgg3.2396.

    PMID: 38353053
  21. 21

    ZTTK Syndrome Expanding the Cardiac Phenotype: A Case of Shone's Complex With a Novel SON Variant and Focused Review of the Cardiac Manifestations in ZTTK Syndrome.

    Coleman J, Shakerdi AL, Dvorakova V, Kenny J

    Case reports in genetics 2026; (2026()):3473063 doi:10.1155/crig/3473063.

    PMID: 42756707
  22. 22

    A novel de novo frameshift variation in the SON gene causing severe global developmental delay and seizures in a Chinese female.

    Yi Z, Song Z, Li F, et al.

    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 2022; (82(3)):271-276 doi:10.1002/jdn.10170.

    PMID: 35080253
  23. 23

    Short stature and growth hormone deficiency in a subset of patients with Potocki-Lupski syndrome: Expanding the phenotype of PTLS.

    Franciskovich R, Soler-Alfonso C, Neira-Fresneda J, et al.

    American journal of medical genetics. Part A 2020; (182(9)):2077-2084 doi:10.1002/ajmg.a.61741.

    PMID: 32656927
  24. 24

    Growth outcomes following recombinant human growth hormone therapy in Zhu-Tokita-Takenouchi-Kim syndrome.

    Lee SC, Muflihi Y, Mohammed Z, et al.

    JCEM case reports 2026; (4(10)):luag247 doi:10.1210/jcemcr/luag247.

    PMID: 42751074
  25. 25

    Enhancing care coordination for neurofibromatosis type 1 in primary care: insights and applications for rare diseases.

    Evans W, Chauhan J, Imam A, Hayward J

    Journal of community genetics 2025; (16(6)):747-757 doi:10.1007/s12687-025-00811-5.

    PMID: 40608210
  26. 26

    Exploring Parents' Values in Healthcare Decision-Making for Rare Genetic Neurodevelopmental Disorders: A Qualitative Study to Inform Guideline Development.

    Klein Haneveld MJ, Cox L, Embregts PJCM, et al.

    Journal of intellectual disability research : JIDR 2026; (70(9)):913-922 doi:10.1111/jir.70150.

    PMID: 42571921
  27. 27

    Care Coordination Using a Shared Plan of Care Approach: From Model to Practice.

    McAllister JW, Keehn RM, Rodgers R, Lock TM

    Journal of pediatric nursing 2018; (43()):88-96 doi:10.1016/j.pedn.2018.09.009.

    PMID: 30473161

This page is for informational purposes only and does not constitute medical advice. A clinical geneticist and the individual's treating specialists should tailor monitoring and treatment for ZTTK, RAUST, or MTSS2-related IDDOF to the person's gene, symptoms, and needs.